BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 31, 2003
 |  BioCentury  |  Tools & Techniques

Excigen provides an electric opportunity

Genzyme Biosurgery has tapped into cardiovascular gene therapy IP from start-up company Excigen Inc. to add to its cardiothoracic portfolio of biomaterials and biotherapeutics, including gene- and cell-based therapies. The partnership will put a commercial platform on top of a base of research into the electrophysiology of the cardiovascular system built by Excigen founders Eduardo Marban and J. Kevin Donahue, both physicians at Johns Hopkins University School of Medicine. The goal is to be in the clinic in three years.

Much of Marban's work has centered on the mechanisms and pathways of arrhythmias, and understanding how best to ameliorate the condition that often...

Read the full 498 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >